Bicycle Therapeutics (BCYC) Price & Analysis

Compare

382 Followers

BCYC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.10 - $28.67

Previous CloseN/A

Volume92.63K

Average Volume (3M)276.83K

Market Cap

$511.09M

Enterprise Value-$232.16M

Total Cash (Recent Filing)$721.45M

Total Debt (Recent Filing)$7.20M

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Oct 30, 2025

EPS Estimate

-1.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.14

Shares Outstanding49,868,570

10 Day Avg. Volume291,270

30 Day Avg. Volume276,829

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.45

Enterprise Value/Revenue-12.04

Enterprise Value/Gross Profit5.96

Enterprise Value/Ebitda0.84

Forecast

1Y Price Target

$23.25

Price Target Upside212.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Financial PerformanceBCYC ended with $721.5M in cash and equivalents, extending their cash runway guidance into 2028 due to strategic cost-cutting efforts.

Pipeline DevelopmentBicycle Therapeutics aims to present initial human imaging data from its EphA2 targeting radioconjugate pipeline, which has potential applications in various cancers.

Regulatory ProgressThe company plans to meet with the FDA to discuss next steps for zelenectide pevedotin, including the potential for accelerated approval.

Bears Say

Adverse EventsKOLs flagged the rate of peripheral neuropathy as one adverse event to monitor closely, given the early follow-up time point.

Clinical SetbacksBCYC announced the pause of the planned Phase I/II Duravelo-5 study in multiple tumor types with Nectin-4 amplification.

Workforce ReductionRestructuring involves a significant workforce reduction of 25% to cut costs by approximately 30%.

Bicycle Therapeutics News

Bicycle Therapeutics price target lowered to $10 from $22 at Citizens JMP

Citizens JMP lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $10 from $22 and keeps an...

5d ago

BCYC

Bicycle Therapeutics price target raised to $27 from $25 at RBC Capital

RBC Capital analyst Leonid Timashev raised the firm’s price target on Bicycle Therapeutics (BCYC) to $27 from $25...

6d ago

BCYC

Bicycle Therapeutics price target lowered to $44 from $48 at Oppenheimer

Oppenheimer analyst Jay Olson lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $44 from $48 and...

6d ago

BCYC

Bicycle Therapeutics files $500M mixed securities shelf

16:08 EDT Bicycle Therapeutics (BCYC) files $500M mixed securities shelf Published first on TheFly – the ultimate source...

9d ago

BCYC

Bicycle Therapeutics reports Q2 EPS ($1.14), consensus (93c)

Reports Q2 revenue $2.92M, consensus $9.43M. “We continue to execute on our strategy, which is grounded in scientific...

9d ago

BCYC

Bicycle Therapeutics Reports Q2 2025 Financial Results

Bicycle Therapeutics ( ($BCYC) ) has released its Q2 earnings. Here is a breakdown of the information Bicycle...

6d ago

BCYC

Bicycle Therapeutics: Strategic Restructuring and Promising Pipeline Drive Buy Rating

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Bicycle Therapeutics, with...

6d ago

BCYC

Bicycle Therapeutics: Strategic Cost Reduction and Program Advancements Justify Buy Rating

Bicycle Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from...

9d ago

BCYC

Bicycle Therapeutics Appoints Charles Swanton to Board

Bicycle Therapeutics ( ($BCYC) ) has shared an announcement. On August 6, 2025, Bicycle Therapeutics announced the appointment...

9d ago

BCYC

Bicycle Therapeutics price target lowered to $25 from $32 at RBC Capital

RBC Capital lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $25 from $32 and keeps an...

1M ago

BCYC

Bicycle Therapeutics Approves Proposals at Annual Meeting

The latest update is out from Bicycle Therapeutics ( ($BCYC) ). On June 17, 2025, Bicycle Therapeutics held...

2M ago

BCYC

Bicycle Therapeutics price target raised to $17 from $15 at Morgan Stanley

Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Bicycle Therapeutics (BCYC) to $17 from $15...

3M ago

BCYC

Bicycle Therapeutics: Strong Pipeline Progress and Strategic Expansion Support Buy Rating

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Bicycle Therapeutics (BCYC – Research Report) on May...

3M ago

BCYC

Bicycle Therapeutics price target lowered to $14 from $17 at B. Riley

B. Riley lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $14 from $17 and keeps a...

4M ago

BCYC

BCYC FAQ

What was Bicycle Therapeutics Ltd’s price range in the past 12 months?

Bicycle Therapeutics Ltd lowest stock price was $6.10 and its highest was $28.67 in the past 12 months.

What is Bicycle Therapeutics Ltd’s market cap?

Bicycle Therapeutics Ltd’s market cap is $511.09M.

When is Bicycle Therapeutics Ltd’s upcoming earnings report date?

Bicycle Therapeutics Ltd’s upcoming earnings report date is Oct 30, 2025 which is in 74 days.

How were Bicycle Therapeutics Ltd’s earnings last quarter?

Bicycle Therapeutics Ltd released its earnings results on Aug 08, 2025. The company reported -$1.14 earnings per share for the quarter, missing the consensus estimate of -$0.946 by -$0.194.

Is Bicycle Therapeutics Ltd overvalued?

According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bicycle Therapeutics Ltd pay dividends?

Bicycle Therapeutics Ltd does not currently pay dividends.

What is Bicycle Therapeutics Ltd’s EPS estimate?

Bicycle Therapeutics Ltd’s EPS estimate is -1.07.

How many shares outstanding does Bicycle Therapeutics Ltd have?

Bicycle Therapeutics Ltd has 49,868,570 shares outstanding.

What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?

Bicycle Therapeutics Ltd reported an EPS of -$1.14 in its last earnings report, missing expectations of -$0.946. Following the earnings report the stock price went up 2.547%.

Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?

Currently, no hedge funds are holding shares in BCYC

Bicycle Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-31.58%

Trailing 12-Months

Asset Growth

-21.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bicycle Therapeutics Ltd

Bicycle Therapeutics (BCYC) is a biotechnology company focused on developing innovative therapies based on its proprietary Bicycle platform, which leverages bicyclic peptides to create a new class of medicines. The company operates primarily in the fields of oncology and other serious diseases, aiming to address unmet medical needs through targeted therapeutics. Bicycle Therapeutics is engaged in the discovery and development of a range of product candidates, including its lead compound BT5528 and various collaborations with pharmaceutical partners to enhance treatment options for patients.

Bicycle Therapeutics (BCYC) Earnings & Revenues

Historic Earnings Reports

BCYC Stock 12 Month Forecast

Average Price Target

$23.25

▲(212.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","45":"$45","15.75":"$15.75","25.5":"$25.5","35.25":"$35.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.75,25.5,35.25,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.99,10.76,13.530000000000001,16.3,19.07,21.84,24.61,27.380000000000003,30.15,32.92,35.69,38.46,41.230000000000004,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.99,9.163846153846155,10.337692307692308,11.51153846153846,12.685384615384615,13.85923076923077,15.033076923076923,16.206923076923076,17.380769230769232,18.55461538461538,19.728461538461538,20.902307692307694,22.076153846153844,{"y":23.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.99,7.913846153846154,7.837692307692308,7.7615384615384615,7.685384615384615,7.609230769230769,7.533076923076923,7.456923076923077,7.380769230769231,7.304615384615385,7.228461538461539,7.1523076923076925,7.076153846153846,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.37,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.71,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >